25 March 2024

Marian Popinigis joins BRP as strategic investor

Marian Popinigis, an entrepreneur and business angel, previously co-founder and CEO of the biotech company BLIRT S.A., which was sold in 2022 to global life science player Qiagen for €60 million, has invested in BioResearch Pharma S.A. (BRP). 

BRP is developing therapies in dermatology, focusing on drug repurposing, which entails the use of known, clinically tested medicinal substances in new therapeutic indications. BRP is advancing treatments with novel mechanisms of action, primarily targeting androgenetic alopecia (BRP-011 project) and psoriasis (BRP-007 project).

“The founders of BioResearch Pharma convinced me first and foremost by all of the solid results of their research to date on substances already known on the market, but with an innovative mechanism of action, and with their impressive experience developing new drugs” said Marian Popinigis, BRP S.A. shareholder and co-founder and co-author of the success of companies like BLIRT S.A. and Mercor S.A. “In addition, BRP’s business model based on dermatology and drug repurposing has significantly greater likelihood of technological and regulatory success, according to independent market analyses. The results obtained by Prof. Katarzyna Koziak in her research were world-class discoveries and allowed her to obtain patent protection. Analyses by CRO IQVIA, the largest global company monitoring the pharmaceutical market, further confirm the potential of BRP’s innovation. The company is developing therapies that may become the new standard in the treatment of alopecia and psoriasis, and improve the quality of life of patients, which also meets the demands of the booming field of aesthetic medicine. An inspiring example of a similar strategy was Allergan, an aesthetic medicine drug developed by Botox that was also a huge market success before being acquired by Abbvie.”

Contact us

    *Required field
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.